MRVI Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -151.9% compared to Maravai LifeSciences Holdings's net margin of 3.36%. Maravai LifeSciences Holdings's return on equity of -29.18% beat Astrana Health's return on equity of 12.67%.

Maravai LifeSciences Holdings has a consensus price target of $9.07, signalling upside risk potential of 68.8%. On the other hand Astrana Health has an analysts' consensus of $64.5000 which suggests that it could grow by 91.4%. Given that Astrana Health has higher upside potential than Maravai LifeSciences Holdings, analysts believe Astrana Health is more attractive than Maravai LifeSciences Holdings.

Maravai LifeSciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.363%.

Maravai LifeSciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maravai LifeSciences Holdings pays -- of its earnings as a dividend. Astrana Health pays out 102.24% of its earnings as a dividend.

Maravai LifeSciences Holdings quarterly revenues are $65.2M, which are smaller than Astrana Health quarterly revenues of $478.7M. Maravai LifeSciences Holdings's net income of -$99M is lower than Astrana Health's net income of $16.1M. Notably, Maravai LifeSciences Holdings's price-to-earnings ratio is -- while Astrana Health's PE ratio is 25.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maravai LifeSciences Holdings is 2.63x versus 0.93x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Codexis has a net margin of -151.9% compared to Maravai LifeSciences Holdings's net margin of -160.84%. Maravai LifeSciences Holdings's return on equity of -29.18% beat Codexis's return on equity of -79.15%.

Maravai LifeSciences Holdings has a consensus price target of $9.07, signalling upside risk potential of 68.8%. On the other hand Codexis has an analysts' consensus of $6.86 which suggests that it could grow by 35.73%. Given that Maravai LifeSciences Holdings has higher upside potential than Codexis, analysts believe Maravai LifeSciences Holdings is more attractive than Codexis.

Maravai LifeSciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Codexis has a beta of 2.155, suggesting its more volatile than the S&P 500 by 115.515%.

Maravai LifeSciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Codexis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maravai LifeSciences Holdings pays -- of its earnings as a dividend. Codexis pays out -- of its earnings as a dividend.

Maravai LifeSciences Holdings quarterly revenues are $65.2M, which are larger than Codexis quarterly revenues of $12.8M. Maravai LifeSciences Holdings's net income of -$99M is lower than Codexis's net income of -$20.6M. Notably, Maravai LifeSciences Holdings's price-to-earnings ratio is -- while Codexis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maravai LifeSciences Holdings is 2.63x versus 5.77x for Codexis. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health has a net margin of -151.9% compared to Maravai LifeSciences Holdings's net margin of -3.72%. Maravai LifeSciences Holdings's return on equity of -29.18% beat Evolent Health's return on equity of -6.81%.

Maravai LifeSciences Holdings has a consensus price target of $9.07, signalling upside risk potential of 68.8%. On the other hand Evolent Health has an analysts' consensus of -- which suggests that it could grow by 123.62%. Given that Evolent Health has higher upside potential than Maravai LifeSciences Holdings, analysts believe Evolent Health is more attractive than Maravai LifeSciences Holdings.

Maravai LifeSciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Evolent Health has a beta of 1.448, suggesting its more volatile than the S&P 500 by 44.822%.

Maravai LifeSciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolent Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maravai LifeSciences Holdings pays -- of its earnings as a dividend. Evolent Health pays out -16.63% of its earnings as a dividend.

Maravai LifeSciences Holdings quarterly revenues are $65.2M, which are smaller than Evolent Health quarterly revenues of $621.4M. Maravai LifeSciences Holdings's net income of -$99M is lower than Evolent Health's net income of -$23.1M. Notably, Maravai LifeSciences Holdings's price-to-earnings ratio is -- while Evolent Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maravai LifeSciences Holdings is 2.63x versus 0.53x for Evolent Health. Usually stocks with elevated PS ratios are considered overvalued.

Fortrea Holdings has a net margin of -151.9% compared to Maravai LifeSciences Holdings's net margin of -4.13%. Maravai LifeSciences Holdings's return on equity of -29.18% beat Fortrea Holdings's return on equity of -18.75%.

Maravai LifeSciences Holdings has a consensus price target of $9.07, signalling upside risk potential of 68.8%. On the other hand Fortrea Holdings has an analysts' consensus of $23.29 which suggests that it could grow by 20.93%. Given that Maravai LifeSciences Holdings has higher upside potential than Fortrea Holdings, analysts believe Maravai LifeSciences Holdings is more attractive than Fortrea Holdings.

Maravai LifeSciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortrea Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Maravai LifeSciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortrea Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maravai LifeSciences Holdings pays -- of its earnings as a dividend. Fortrea Holdings pays out -- of its earnings as a dividend.

Maravai LifeSciences Holdings quarterly revenues are $65.2M, which are smaller than Fortrea Holdings quarterly revenues of $674.9M. Maravai LifeSciences Holdings's net income of -$99M is lower than Fortrea Holdings's net income of -$27.9M. Notably, Maravai LifeSciences Holdings's price-to-earnings ratio is -- while Fortrea Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maravai LifeSciences Holdings is 2.63x versus 0.58x for Fortrea Holdings. Usually stocks with elevated PS ratios are considered overvalued.